C. Purdy

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

B. Monk, R. Burger, E. Swisher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulation after conservative therapy for the management of fecal incontinence.

M. Bernstein, A. Becker, R. Magar, 2014, Clinical therapeutics.

Racial Disparities in Cancer Screening Among Women with Chronic Joint Pain

E. Williams, Laurene Tumiel-Berhalter, Judith Anderson, 2010 .

Abstract CT151: A Phase II study of NLG207 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

P. Thaker, C. Link, Austin Miller, 2019, Clinical Trials.

Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts

R. Santos-Oliveira, T. Einarson, C. Purdy, 2011, Diabetologia.

A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.

M. Pimentel, A. Rezaie, R. Magar, 2016, Clinical therapeutics.

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

P. Thaker, J. Supko, S. Modesitt, 2020, Gynecologic oncology.

Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.

S. Waggoner, M. Kelly, A. Wolfson, 2021, Gynecologic oncology.

Cost-Minimization For A Novel Ibs Diagnostic Blood Panel Versus Standard Exclusionary Diagnostic Testing For Diarrhea Predominant Irritable Bowel Syndrome: A United States Perspective.

M. Pimentel, R. Magar, C. Purdy, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.